Q4 2024 KEY INDICATORS

• Revenues amounted to 84.1 MSEK (59.5)
• Revenues (excluding PPA adjustments) amounted to 88.8 MSEK (59.5)
• EBITDA equaled 20.1 MSEK (9.3)
• EBITDA (excluding PPA adjustments) equaled 24.8 MSEK (9.3)
• Operating profit (EBIT) is 4.0 MSEK (5.9)
• Operating profit (EBIT), (excluding PPA adjustments) is 8.7 MSEK (5.9)
• Earnings per share SEK -0,04 (0,38) per share

 
JAN-DEC 2024 KEY INDICATORS

• Revenues amounted to 256.2 MSEK (183.2)
• Revenues (excluding PPA adjustments) amounted to 260.9 MSEK (183.2)
• EBITDA equaled 58.9 MSEK (31.1)
• EBITDA (excluding PPA adjustments) equaled 63.6 MSEK (31.1)
• Operating profit (EBIT) is 23.2 MSEK (18.0)
• Operating profit (EBIT), (excluding PPA adjustments) is 27.9 MSEK (18.0)
• Earnings per share SEK 0,93 (1,13) per share

 
”Magle Group’s Q4 interim report highlights a year of solid growth, strategic expansion, and innovation across its core business areas. Increased adoption of SmartPAN® and EmboCept®S drove continued momentum in the DSM segment, while the CDMO business experienced steady growth through rising demand and strengthened client relationships. The successful integration of PK Chemical into Magle Biopolymers and Amniotics into Magle Biopharma has already delivered operational synergies and revenue contributions. The Purchase Price Allocation (PPA) for both acquisitions, remains preliminary, as we continue to evaluate the assets within the businesses and bring them to their full potential. Investments in new technologies, including dextran-based solutions and amniotic stem cells, have further diversified the innovation pipeline. Despite short-term cost impacts from acquisitions and infrastructure upgrades, these initiatives position Magle Group for long-term profitability and leadership in the biopolymer and advanced therapeutics space.” says Justin Pierce, CEO